Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Edwards Lifesciences Corporation $EW

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,364 shares of the medical research company’s stock, valued at approximately $1,395,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Vise Technologies Inc. lifted its position in Edwards Lifesciences by 6.2% in the 4th quarter. Vise Technologies Inc. now owns 7,113 shares of the medical research company’s stock valued at $606,000 after acquiring an additional 417 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Edwards Lifesciences by 2.7% during the 4th quarter. Daiwa Securities Group Inc. now owns 136,461 shares of the medical research company’s stock valued at $11,634,000 after purchasing an additional 3,616 shares during the last quarter. Crescent Grove Advisors LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth approximately $211,000. Cibc World Market Inc. increased its holdings in Edwards Lifesciences by 37.3% during the 4th quarter. Cibc World Market Inc. now owns 33,601 shares of the medical research company’s stock worth $2,864,000 after purchasing an additional 9,120 shares in the last quarter. Finally, TD Asset Management Inc raised its stake in shares of Edwards Lifesciences by 6.4% in the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock worth $66,335,000 after purchasing an additional 47,051 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

EW stock opened at $87.62 on Friday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The firm has a market cap of $50.45 billion, a PE ratio of 46.61, a P/E/G ratio of 2.16 and a beta of 0.87. The business has a 50 day moving average of $82.15 and a 200-day moving average of $83.04. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $89.14.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EW. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Piper Sandler reissued an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Evercore reiterated an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Finally, Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $95.96.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the transaction, the vice president owned 33,934 shares in the company, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 95,057 shares of company stock valued at $7,874,217 in the last three months. Company insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.